NO20076588L - Sammensetninger som omfatter blodplateagregeringsinhibitor i nanopartikkelform og med kontrollert frigjoring - Google Patents

Sammensetninger som omfatter blodplateagregeringsinhibitor i nanopartikkelform og med kontrollert frigjoring

Info

Publication number
NO20076588L
NO20076588L NO20076588A NO20076588A NO20076588L NO 20076588 L NO20076588 L NO 20076588L NO 20076588 A NO20076588 A NO 20076588A NO 20076588 A NO20076588 A NO 20076588A NO 20076588 L NO20076588 L NO 20076588L
Authority
NO
Norway
Prior art keywords
platelet aggregation
aggregation inhibitor
nano
compositions
particle
Prior art date
Application number
NO20076588A
Other languages
English (en)
Inventor
Gurvinder Singh Rekhi
Gary Liversidge
Scott Jenkins
John Devane
Niall Fanning
Paul Stark
Original Assignee
Elan Pharma Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma Int Ltd filed Critical Elan Pharma Int Ltd
Publication of NO20076588L publication Critical patent/NO20076588L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Den foreliggende oppfinnelsen tilveiebringer en sammensetning som omfatter en blodplateaggregeringshemmer, for eksempel cilostazol eller et salt eller derivat av dette, som kan brukes ved behandlingen eller ved forebygging av iskemiske symptomer. Oppfinnelsen tilveiebringer en sammensetning som omfatter nanopartikler som omfatter blodplateaggregeringshemmeren og minst én overflatestabilisator. Nanopartiklene har en effektiv midlere partikkelstørrelse på mindre enn omtrent 2000 nm. Oppfinnelsen tilveiebringer også en sammensetning som leverer en blodplateaggregeringshemmer eller nanopartikler som inneholder denne, på en pulserende eller kontinuerlig måte.
NO20076588A 2005-05-23 2007-12-20 Sammensetninger som omfatter blodplateagregeringsinhibitor i nanopartikkelform og med kontrollert frigjoring NO20076588L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68362005P 2005-05-23 2005-05-23
PCT/US2006/019905 WO2008030209A2 (en) 2005-05-23 2006-05-23 Nanoparticulate and controlled release compositions comprising a platelet aggregation inhibitor

Publications (1)

Publication Number Publication Date
NO20076588L true NO20076588L (no) 2008-02-20

Family

ID=39153748

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076588A NO20076588L (no) 2005-05-23 2007-12-20 Sammensetninger som omfatter blodplateagregeringsinhibitor i nanopartikkelform og med kontrollert frigjoring

Country Status (12)

Country Link
US (1) US20090297596A1 (no)
EP (1) EP1937218A2 (no)
JP (1) JP2008545808A (no)
KR (1) KR20080047509A (no)
CN (1) CN101287451A (no)
BR (1) BRPI0609982A2 (no)
CA (1) CA2611506A1 (no)
EA (1) EA200702595A1 (no)
IL (1) IL187567A0 (no)
NO (1) NO20076588L (no)
WO (1) WO2008030209A2 (no)
ZA (1) ZA200710000B (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9775819B2 (en) 2009-09-16 2017-10-03 R.P. Scherer Technologies, Llc Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin
US8779146B2 (en) 2010-04-28 2014-07-15 Nuformix Limited Cilostazol cocrystals and compositions
US9012511B2 (en) 2010-05-19 2015-04-21 Alkermes Pharma Ireland Limited Nanoparticulate cinacalcet compositions
KR101282847B1 (ko) * 2011-07-27 2013-07-05 조선대학교산학협력단 실로스타졸을 함유하는 고체분산체 및 이를 포함하는 약학 조성물
MX2014015310A (es) * 2012-06-15 2015-07-06 Found Biomedical Res & Innov Agente profilactico y/o terapeutico para el deterioro cognoscitivo leve.
TWI697337B (zh) * 2013-08-07 2020-07-01 學校法人近畿大學 奈米粒子或奈米粒子組成物之製造方法，及支架或球囊導管之製造方法
CN103980326A (zh) * 2014-05-05 2014-08-13 珀莱雅化妆品股份有限公司 一种超临界co2反胶束萃取红景天苷的制备方法
KR101869406B1 (ko) * 2015-11-25 2018-07-24 한국유나이티드제약 주식회사 방출제어형 경질캡슐 제제
CN112592379B (zh) * 2020-12-18 2021-11-16 广东药科大学 一种β-D-葡萄糖短链脂肪酸酯化合物及其制备方法和应用
CN114796217B (zh) * 2021-01-29 2025-01-24 南京宁丹新药技术有限公司 一种含有西洛他唑的组合物在制备治疗脑血管病药物中的应用
CN117982677B (zh) * 2024-02-05 2025-09-09 沈阳药科大学 背载血小板激活抑制剂纳米粒的工程化血小板及其制备方法及应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU677783B2 (en) * 1992-06-10 1997-05-08 Elan Pharma International Limited Surface modified nsaid nanoparticles
US6117455A (en) * 1994-09-30 2000-09-12 Takeda Chemical Industries, Ltd. Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
CA2348871C (en) * 1998-11-02 2009-04-14 John G. Devane Multiparticulate modified release composition
EG23951A (en) * 1999-03-25 2008-01-29 Otsuka Pharma Co Ltd Cilostazol preparation
JP4748839B2 (ja) * 1999-03-25 2011-08-17 大塚製薬株式会社 シロスタゾール製剤
JP4641696B2 (ja) * 1999-09-30 2011-03-02 大塚製薬株式会社 消化管下部溶解性コーティング製剤
EP1267946A4 (en) * 2000-02-28 2008-07-02 Genesegues Inc SYSTEM AND METHOD FOR ENCAPSULATING NANOCAPSULES
EP1341521B1 (en) * 2000-11-20 2009-01-07 Elan Pharma International Limited Nanoparticulate compositions comprising a drug and copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
US6573382B2 (en) * 2001-06-29 2003-06-03 Grayson Walker Stowell Polymorphic forms of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone
JP2004537401A (ja) * 2001-08-08 2004-12-16 ブラウン ユニバーシティ リサーチ ファウンデーション 疎水性薬物の微粉砕方法
TW200301135A (en) * 2001-12-27 2003-07-01 Otsuka Maryland Res Inst Inc Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor
US8512727B2 (en) * 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
CA2534924A1 (en) * 2003-08-08 2005-02-24 Elan Pharma International Ltd. Novel metaxalone compositions
US20050255155A1 (en) * 2004-05-11 2005-11-17 Glenmark Pharmaceuticals Limited Modified release cilostazol compositions
JP2008540546A (ja) * 2005-05-10 2008-11-20 エラン ファーマ インターナショナル リミテッド ナノ粒子クロピドグレル製剤
CA2611741A1 (en) * 2005-06-13 2006-12-28 Elan Pharma International, Limited Nanoparticulate clopidogrel and aspirin combination formulations

Also Published As

Publication number Publication date
CA2611506A1 (en) 2006-11-23
BRPI0609982A2 (pt) 2010-05-18
EP1937218A2 (en) 2008-07-02
EA200702595A1 (ru) 2008-12-30
WO2008030209A3 (en) 2008-07-03
US20090297596A1 (en) 2009-12-03
ZA200710000B (en) 2009-12-30
IL187567A0 (en) 2011-08-01
KR20080047509A (ko) 2008-05-29
CN101287451A (zh) 2008-10-15
JP2008545808A (ja) 2008-12-18
WO2008030209A2 (en) 2008-03-13

Similar Documents

Publication Publication Date Title
NO20076692L (no) Nanopartikulaere acetaminofenformuleringer
NO20076215L (no) Nanopartikulaere clopidogrelformuleringer
MX2010009866A (es) Composiciones de inhibidores de angiogenesis en nanoparticulas.
HK1254398A1 (zh) 納米粒子組合物的生物標誌物
AR063940A1 (es) Formulaciones de posaconazol nanoparticulado
NO20092639L (no) 4-fenyl-6-(2,2,2-trifluor-1-fenyletoksy)pynmidinbaserte forbindelser og anvendelser derav
WO2008143633A3 (en) Compounds and methods for treatment of alpha-1 antitrypsin deficiency
BRPI0409100A (pt) composição conservante de madeira, e, métodos para conservar um produto de madeira e madeira
WO2009115267A3 (de) Diaminopyrimidine als pflanzenschutzmittel
WO2008035246A3 (en) Compositions containing quaternary ammonium compounds
AU2003230692A8 (en) Nanoparticulate compositions of map kinase inhibitors
WO2006110809A3 (en) Nanoparticulate lipase inhibitor formulations
WO2008089389A3 (en) Treatment of cancers with acquired resistance to kit inhibitors
WO2010048149A3 (en) Heterocyclic modulators of gpr119 for treatment of disease
WO2006133396A3 (en) Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1) pathway
MX2009009948A (es) Derivados de piridazinona utiles como inhibidores de glucano sintasa.
WO2010048623A3 (en) Medical and imaging nanoclusters
WO2007015866A3 (en) Inhibitors of p38 kinase and methods of treating inflammatory disorders
SA520412434B1 (ar) تركيبات، مجموعات، طرق واستخدامات للتنظيف، التطهير، التعقيم و/أو العلاج
PH12015500678A1 (en) Crystalline forms of a factor xia inhibitor
ATE431131T1 (de) Meloxican-formulierungen in nanoteilchenform
NO20076628L (no) Nanopartikkulaere sammensetninger med kontrollert frigjoring som omfatter arylheterosykliske forbindelser
PH12012502260A1 (en) Liquid formulations of rupatadine fumarate
NO20090379L (no) Nanopartikulaere formuleringer av modafinil
WO2010065587A3 (en) Ferroelectric nanoshell devices

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application